RxDoctor Payments Data

Muhammad Ghazi, MD

Family Medicine · Jacksonville, FLNPI 1073830725

Payments from drug & device makers

$972in general payments, 2019–2025

Across 57 payments — averaging $17.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$174
  • Dexcom, Inc.$147
  • Amgen$134
  • Novo Nordisk$126
  • Lilly USA, LLC$81
  • AbbVie$65
  • plus $246 from 12 others

What the payments were for

  • Food & beverage$96599%
  • Education$71%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$972 in reported general payments places this provider in the 60th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$91,334
Medicare patients
293
Services billed
1,769

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide139$165,654
TrulicityDulaglutide98$125,670
JardianceEmpagliflozin136$121,687
EliquisApixaban47$48,543
JanuviaSitagliptin Phosphate56$38,237
TradjentaLinagliptin39$27,534
RybelsusSemaglutide20$18,550
FarxigaDapagliflozin Propanediol15$17,934
MounjaroTirzepatide11$15,086
TrintellixVortioxetine Hydrobromide18$12,578
MyrbetriqMirabegron24$11,568
Lantus SolostarInsulin Glargine,hum.Rec.Anlog85$10,654
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$9,596
Spiriva RespimatTiotropium Bromide15$7,660
Gvoke Pfs 1-Pack SyringeGlucagon14$4,887

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$126$184,204159 claims
Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat$38$156,881190 claims
Lilly USA, LLCTrulicity, Mounjaro$81$140,756109 claims
PfizerEliquis$28$48,54347 claims
AstraZenecaFarxiga$174$17,93415 claims
AbbVieSynthroid$65$1,53513 claims
Sanofi-aventis U.S. LLCLantus$12$1,44213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Jacksonville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →